Literature DB >> 24605347

Dermatologic complications from levamisole-contaminated cocaine: a case report and review of the literature.

Erich M Gaertner1, Stephen A Switlyk.   

Abstract

Levamisole is a veterinary anthelmintic drug with immunomodulatory properties in humans. It has become increasingly common as a contaminant in cocaine and is now detected in the majority of cocaine seized in the United States. A variety of adverse reactions have been reported in association with levamisole, the most severe being agranulocytosis, vascular occlusive disease, and thrombotic vasculopathy, with or without vasculitis. The combination of rapidly progressive cutaneous ecchymosis and purpura leading to necrosis, often affecting the ears and cheeks; neutropenia or agranulocytosis; serologic autoantibodies; and thrombotic vasculopathy, with or without associated vasculitis, in a patient who has recently used cocaine is characteristic of exposure to contaminant levamisole. We report the case of a 54-year-old man who presented with the clinical findings of levamisole-contaminated cocaine use and review the literature regarding cutaneous reactions associated with levamisole. Our case highlights this important public health issue and represents a clinical course that is unusually severe.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24605347

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Emerging and Underrecognized Complications of Illicit Drug Use.

Authors:  Alysse G Wurcel; Elisabeth A Merchant; Roger P Clark; David R Stone
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

Review 2.  Pathologic manifestations of levamisole-adulterated cocaine exposure.

Authors:  Amber L Nolan; Kuang-Yu Jen
Journal:  Diagn Pathol       Date:  2015-05-06       Impact factor: 2.644

Review 3.  Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders.

Authors:  Swarup Mitra; Shailesh N Khatri; Malabika Maulik; Abel Bult-Ito; Marvin Schulte
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.